IL129387A0 - Methods and compositions for delivery and expression of interferon-alpha nucleic acids - Google Patents

Methods and compositions for delivery and expression of interferon-alpha nucleic acids

Info

Publication number
IL129387A0
IL129387A0 IL12938797A IL12938797A IL129387A0 IL 129387 A0 IL129387 A0 IL 129387A0 IL 12938797 A IL12938797 A IL 12938797A IL 12938797 A IL12938797 A IL 12938797A IL 129387 A0 IL129387 A0 IL 129387A0
Authority
IL
Israel
Prior art keywords
interferon
expression
delivery
compositions
methods
Prior art date
Application number
IL12938797A
Other languages
English (en)
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of IL129387A0 publication Critical patent/IL129387A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
IL12938797A 1996-10-18 1997-10-16 Methods and compositions for delivery and expression of interferon-alpha nucleic acids IL129387A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73381596A 1996-10-18 1996-10-18
PCT/US1997/017928 WO1998017801A1 (en) 1996-10-18 1997-10-16 METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-α NUCLEIC ACIDS

Publications (1)

Publication Number Publication Date
IL129387A0 true IL129387A0 (en) 2000-02-17

Family

ID=24949214

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12938797A IL129387A0 (en) 1996-10-18 1997-10-16 Methods and compositions for delivery and expression of interferon-alpha nucleic acids

Country Status (20)

Country Link
EP (2) EP0932679A1 (es)
JP (2) JP2001502540A (es)
KR (1) KR20000049243A (es)
AR (1) AR013618A1 (es)
AU (1) AU4808097A (es)
BR (1) BR9712362A (es)
CA (1) CA2269100A1 (es)
CZ (1) CZ131699A3 (es)
DE (1) DE932679T1 (es)
ES (1) ES2136583T1 (es)
HU (1) HUP9904219A2 (es)
ID (1) ID24500A (es)
IL (1) IL129387A0 (es)
NO (1) NO991839L (es)
NZ (1) NZ335134A (es)
PL (1) PL332856A1 (es)
SK (1) SK50699A3 (es)
TR (1) TR199901190T2 (es)
WO (1) WO1998017801A1 (es)
ZA (1) ZA979295B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912925D0 (en) * 1999-06-03 1999-08-04 Angeletti P Ist Richerche Bio Adenoviral vectors encoding interferon and their use in gene therapy
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
EP1694850B1 (en) 2003-11-12 2011-06-29 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
ES2363912T3 (es) 2003-12-10 2011-08-19 Canji, Inc. Procedimientos y composiciones para el tratamiento de tumores resistentes a interferon.
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
KR101470472B1 (ko) 2006-09-14 2014-12-09 메드제닉스 메디칼 이스라엘 리미티드 장기 지속형 약물 제형
ES2439954T3 (es) * 2007-02-23 2014-01-27 Her Majesty The Queen, In Right Of Canada, As Represented By The Minister Of National Defence Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
WO2010142017A1 (en) 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
CA2802726A1 (en) 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations
AU2018246292A1 (en) 2017-03-31 2019-10-10 Accanis Biotech F&E Gmbh & Co Kg Prevention and treatment of non-melanoma skin cancer (NMSC)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238778C2 (de) * 1992-11-12 1995-11-02 Max Delbrueck Centrum Vektor zur Expression von therapeutisch relevanten Genen
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
PT797676E (pt) * 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
DE4407859C1 (de) * 1994-03-04 1995-03-02 Max Planck Gesellschaft Vektor für die leberspezifische Gentherapie
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
JP2001502540A (ja) 2001-02-27
JP2008301832A (ja) 2008-12-18
KR20000049243A (ko) 2000-07-25
NO991839D0 (no) 1999-04-16
DE932679T1 (de) 2000-03-09
EP1591528A3 (en) 2005-11-16
ID24500A (id) 2000-07-20
ZA979295B (en) 1998-04-20
HUP9904219A2 (hu) 2000-12-28
AR013618A1 (es) 2001-01-10
PL332856A1 (en) 1999-10-25
CA2269100A1 (en) 1998-04-30
AU4808097A (en) 1998-05-15
WO1998017801A1 (en) 1998-04-30
EP1591528A2 (en) 2005-11-02
NZ335134A (en) 2001-05-25
TR199901190T2 (xx) 1999-07-21
NO991839L (no) 1999-06-15
ES2136583T1 (es) 1999-12-01
BR9712362A (pt) 1999-08-31
CZ131699A3 (cs) 1999-07-14
EP0932679A1 (en) 1999-08-04
SK50699A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
EP1015470A4 (en) COMPOSITION AND METHOD FOR DELIVERING NUCLEIC ACIDS
AU4231897A (en) Compositions and methods for delivery of nucleic acids to hepatocytes
EP0948513A4 (en) RECOMBINATION PRODUCT FOR THE DELIVERY OF ANTISENSE NUCLEIC ACIDS AND METHODS OF USE
HUP9801207A3 (en) Therapeutic compositions for transfecting nucleic acids and use thereof
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
IL136454A0 (en) Compositions and methods for inducing gene expression
IL132704A0 (en) Methods and compositions for the selective modification of nucleic acids
ZA968907B (en) Compositions and methods for buccal delivery of pharmaceutical agents
HUP0003761A3 (en) Substituted alkanohydroxamic acids and pharmaceutical compositions containing them
EP0975371A4 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR MODULATING THE ACTIVATING PROTEIN 1.
AU6544598A (en) Compositions and methods for analysis of nucleic acids
IL135338A0 (en) Methods and compositions for the selective modification of nucleic acids
IL105914A0 (en) Methods and compositions for in vivo gene therapy
AU9692198A (en) Gene delivery compositions and methods
IL114015A0 (en) Inhibitors of interleukin-1beta converting enzyme and pharmaceutical compositions containing the same
HUP9702035A3 (en) Inhibitors of leukocita-adhesion- and vla-4-antagonists and pharmaceutical compositions containing them
HUP9702036A3 (en) Inhibitors of leucocita-adhesion and wla-4-antagonists and pharmaceutical compositions containing them
HUP9702034A3 (en) Inhibitors of leukocita-adhesion and vla-4-antagonists and pharmaceutical compositions containing them
GB9422571D0 (en) Haemorrihoidal compositions and method of use
AU4008495A (en) Tcl-1 gene and protein and related methods and compositions
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
GB9710800D0 (en) Pharmaceutical composition and method of preparing it
IL129387A0 (en) Methods and compositions for delivery and expression of interferon-alpha nucleic acids
EP0781142A4 (en) COMPOSITIONS AND METHOD FOR PROVIDING POLYPEPTIDES
HUP9700810A3 (en) Acids and esters of diosmetin and pharmaceutical compositions containing them